Gaining Weight After Switching From Mounjaro to Wegovy: What's Happening and What to Do

Step 1: Understand why Mounjaro and Wegovy produce different results in the same person

Mounjaro activates two gut-hormone receptors (GIP and GLP-1) while Wegovy targets GLP-1 alone. That dual-receptor action is the most likely reason tirzepatide consistently produced greater average weight loss in clinical trials. In the SURMOUNT-5 head-to-head study, published in the New England Journal of Medicine in 2025, tirzepatide outperformed semaglutide 2.4mg over 72 weeks in adults with obesity. That gap has real consequences when someone moves from one to the other.

When you stop tirzepatide and start semaglutide, the GIP pathway goes quiet. For many people, appetite control loosens before the new medicine reaches an effective dose. That interval (sometimes several weeks) is when weight creeps back. It's a pharmacological gap, not a failure of willpower. The body was relying on two signals; it's now running on one, at a lower dose than it will eventually reach.

Dose titration matters here. Wegovy starts at 0.25mg and increases over months toward 2.4mg (or higher with the newer 7.2mg maintenance option approved by the MHRA in 2026). Someone who was on 10mg or 15mg tirzepatide and drops to 0.25mg semaglutide overnight will feel the difference. The appetite suppression they were used to simply isn't there yet. More on the mechanics of the switch itself is covered in our guide to switching from Mounjaro to Wegovy.

Step 2: Compare what the evidence actually says about results on each medicine

A side-by-side look at the published trial data helps put the regain in context.

Sources: NICE TA1026 recommendations; NICE TA875. These are trial averages, individual responses vary considerably, which is why a prescriber's view of your specific trajectory matters more than any population figure.

If you're asking whether the switch can work at all, our prescribers get this question most weeks. The answer is: yes, for some people, Wegovy at full maintenance dose performs well. For others, the difference in mechanism is significant enough that returning to tirzepatide makes clinical sense. Our page on whether switching from Mounjaro to Wegovy works covers that question in more depth.

Step 3: Work out whether the weight gain is transitional or structural

Not all post-switch weight gain signals the same thing. There are broadly two patterns, and distinguishing them shapes the clinical response.

The first is transitional regain: weight gained during the dose-escalation phase of Wegovy, before the medicine has reached a therapeutic level. This often stabilises or reverses once a patient reaches 1.7mg or 2.4mg, and potentially more so at 7.2mg. If you switched recently and are still in the early titration steps, it may be too soon to draw conclusions.

The second is structural: the medicine has reached maintenance dose and weight continues rising. This is a stronger signal that semaglutide is simply less effective for you than tirzepatide was. It's not unusual (the individual variation in GLP-1 response is well documented) and it's a clinical conversation worth having promptly rather than waiting months. If you were previously on Ozempic rather than Wegovy and are wondering how tirzepatide compares, our page on switching from Mounjaro to Ozempic for weight loss addresses how that particular transition tends to play out.

Either way, a prescriber needs to see your weight trend, not just today's number. That's why every repeat order through nume involves a real clinician reviewing your progress before anything is issued. If you want to understand the broader comparison between the two medicines, our Wegovy vs Mounjaro overview lays out the evidence clearly.

Step 4: Know your options, including switching back

If Wegovy isn't controlling appetite the way Mounjaro did, three realistic options exist, all of which require prescriber assessment.

First, continue titrating Wegovy to a higher dose. Some patients who regain weight at 1.0mg or 1.7mg see results improve significantly at 2.4mg or beyond. Jumping to a conclusion before reaching maintenance dose is premature, though the timeline should be discussed with your prescriber rather than extended indefinitely.

Second, switch back to tirzepatide. This is a legitimate clinical path. Our page on switching back to Mounjaro from Wegovy covers what that process involves and what to expect. The clinical reviewer will want to understand why the switch happened in the first place (whether it was availability, cost or tolerability) before deciding the right approach.

Third, consider whether the dose on Wegovy is appropriate for your history. Someone stepping across from 15mg tirzepatide needs more careful titration planning than someone who was on 5mg. A prescriber can assess this directly. You can also read about how Wegovy and Mounjaro compare on cost, which is often part of why people switch in the first place. Worth being clear-eyed about: the lower price means little if weight regain follows.

Which of these paths suits your situation is a clinical decision our prescribers make with you, not something to work out from a comparison table alone. Speak to our prescribers through a free consultation and get a view built around your actual weight history.